BATS · GSKH
Precidian ETFs Trust GSK plc
Financial Services · Asset Management
$67.07
Down-$0.25 (-0.37%)
Updated Sep 11, 2026, 10:08 AM
SID Score
3.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 694.47K
- P/E ratio
- —
- Dividend yield
- 1.17%
- 52-week range
- $67.57 – $82.02
- Volume
- 214
- Avg. volume
- 342
Price performance
GSKH price history
1M range · 20 trading sessions · Daily adjusted prices
GSKH closed at $67.07 after 20 trading sessions, down 3.94% for the selected period.
- Last close
- $67.07
- Period change
- -3.94%
- Period low
- $67.07
- Period high
- $73.09
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $67.69 | $67.69 | $67.0681 | $67.0681 | 214 |
| Sep 9, 2026 | $67.73 | $67.73 | $67.6331 | $67.6331 | 125 |
| Sep 8, 2026 | $68.18 | $68.18 | $67.5659 | $67.5659 | 125.01 |
| Sep 4, 2026 | $69.48 | $69.55 | $69.48 | $69.5112 | 225 |
| Sep 3, 2026 | $71.38 | $71.38 | $70.53 | $70.7456 | 211.01 |
| Sep 2, 2026 | $70.39 | $70.39 | $70.3871 | $70.3871 | 223 |
| Sep 1, 2026 | $70.59 | $70.60 | $70.43 | $70.5163 | 324 |
| Aug 31, 2026 | $70.28 | $70.28 | $69.8569 | $69.8569 | 112 |
| Aug 28, 2026 | $69.37 | $70.5267 | $69.35 | $70.5267 | 1.41K |
| Aug 27, 2026 | $69.85 | $70.00 | $69.6792 | $69.6792 | 233 |
| Aug 26, 2026 | $71.49 | $71.49 | $71.2785 | $71.2785 | 218.01 |
| Aug 25, 2026 | $71.14 | $71.8401 | $71.14 | $71.8401 | 215.05 |
| Aug 24, 2026 | $71.36 | $71.5619 | $71.30 | $71.5619 | 212 |
| Aug 21, 2026 | $72.09 | $72.35 | $72.09 | $72.35 | 215 |
| Aug 20, 2026 | $72.14 | $72.35 | $71.59 | $71.6836 | 1.44K |
| Aug 19, 2026 | $72.27 | $73.0903 | $72.27 | $73.0903 | 213 |
| Aug 18, 2026 | $71.1955 | $71.1955 | $71.1955 | $71.1955 | 10 |
| Aug 17, 2026 | $69.64 | $69.8844 | $69.64 | $69.8844 | 228.08 |
| Aug 14, 2026 | $68.25 | $68.9018 | $68.25 | $68.9018 | 229.06 |
| Aug 13, 2026 | $69.56 | $69.8223 | $69.56 | $69.8223 | 223.06 |
Latest GSKH news
The latest Smart Investors Daily articles mentioning GSKH.
Stock researchCompany · Overview
GSKH research
Overview
Company profile and research snapshot.
Company profile
The series, under normal circumstances, invests at least 95% of its net assets in American Depositary Receipts (“ADRs”) of GSK plc (the “Company”). The series will not invest directly in the company. The fund is non-diversified.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
